CINECA IRIS Institutional Research Information System

GERMANI, MARCO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.452
AS - Asia 1.331
EU - Europa 654
SA - Sud America 176
AF - Africa 61
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.404
SG - Singapore 514
CN - Cina 340
IT - Italia 308
HK - Hong Kong 187
BR - Brasile 142
VN - Vietnam 100
SE - Svezia 58
DE - Germania 57
GB - Regno Unito 53
JP - Giappone 38
KR - Corea 38
FR - Francia 33
IN - India 29
FI - Finlandia 28
PL - Polonia 22
CI - Costa d'Avorio 21
BD - Bangladesh 17
NL - Olanda 17
CA - Canada 16
MX - Messico 16
BG - Bulgaria 15
AR - Argentina 13
RU - Federazione Russa 13
IQ - Iraq 10
ZA - Sudafrica 10
AT - Austria 9
UZ - Uzbekistan 9
TR - Turchia 8
EC - Ecuador 7
ES - Italia 7
LT - Lituania 7
SN - Senegal 7
UA - Ucraina 7
CZ - Repubblica Ceca 5
IE - Irlanda 5
MA - Marocco 5
PH - Filippine 5
PK - Pakistan 5
EG - Egitto 4
HN - Honduras 4
ID - Indonesia 4
NG - Nigeria 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
PA - Panama 3
PY - Paraguay 3
AU - Australia 2
AZ - Azerbaigian 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
JO - Giordania 2
KW - Kuwait 2
LY - Libia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
MG - Madagascar 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TJ - Tagikistan 1
TW - Taiwan 1
UY - Uruguay 1
Totale 3.680
Salva come PNG Salva come JPEG
Città #
Singapore 313
San Jose 250
Ashburn 202
Hong Kong 180
Dallas 153
Santa Clara 145
Shanghai 76
Los Angeles 56
Hefei 53
Chandler 51
Milan 45
Beijing 41
Seoul 36
New York 35
Boardman 33
Florence 31
Tokyo 31
Fairfield 29
Hanoi 29
Ho Chi Minh City 29
London 24
Abidjan 21
São Paulo 20
Warsaw 18
Frankfurt am Main 17
Pisa 17
Cascina 15
Munich 15
Rome 15
Sofia 15
Council Bluffs 14
Helsinki 14
Buffalo 13
Lawrence 13
Bremen 12
Chicago 12
Lauterbourg 12
Princeton 12
Houston 11
Seattle 11
Turku 11
Redondo Beach 10
Wilmington 10
Medford 9
Orem 9
Denver 8
Rio de Janeiro 8
Stockholm 8
Woodbridge 8
Dakar 7
Ogden 7
Toronto 7
Ann Arbor 6
Chennai 6
Mumbai 6
Tashkent 6
Turin 6
Vienna 6
Boston 5
Cambridge 5
Dublin 5
Genoa 5
Istanbul 5
Lucca 5
Manchester 5
Montreal 5
Naples 5
Nuremberg 5
Quanzhou 5
Amsterdam 4
Atlanta 4
Baghdad 4
Brooklyn 4
Düsseldorf 4
Fuzhou 4
Guayaquil 4
Johannesburg 4
Kent 4
Lagos 4
Memphis 4
Phoenix 4
Polverigi 4
Porto Alegre 4
San Francisco 4
Verona 4
Bologna 3
Bra 3
Cairo 3
Cape Town 3
Coreglia Antelminelli 3
Da Nang 3
Dhaka 3
Fukuroi 3
Hyderabad 3
Hải Dương 3
Kyiv 3
Misinto 3
Panama City 3
Pistoia 3
Poplar 3
Totale 2.421
Salva come PNG Salva come JPEG
Nome #
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 181
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 156
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 143
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma 139
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 139
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors 133
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 132
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 128
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm 126
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development 124
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 123
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 121
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 121
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer 117
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge 117
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 112
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration 112
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 103
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 102
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 99
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 98
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 97
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer 87
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors 81
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy 81
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 78
EGFR Amplification in Metastatic Colorectal Cancer 76
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV 73
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 72
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 69
null 65
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 56
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials 52
Esperienze cliniche con encorafenib e cetuximab in pazienti con carcinoma metastatico del colon-retto con mutazione BRAFV600E dopo recidiva precoce alla chemioterapia adiuvante 42
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials 38
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO 33
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 33
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study 24
Evaluation of Predictive Markers for Immunotherapy in Colorectal Cancer: Concordance Between MMR Protein Expression and Microsatellite Instability in a Retrospective Series 23
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment 20
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 15
Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer 13
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 13
Totale 3.767
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.549
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 0 0 0 0 0 0 0 0 0 0 0 15
2021/2022104 4 0 4 0 13 15 1 4 9 11 13 30
2022/2023240 22 36 17 14 17 26 6 13 52 0 31 6
2023/2024316 18 23 40 21 34 31 32 8 21 17 39 32
2024/20251.114 15 36 21 45 92 138 77 48 126 96 148 272
2025/20261.923 137 211 151 172 204 135 265 136 125 178 160 49
Totale 3.767